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Abstract 
Aims: Hospitalizations for heart failure (HF) are common and associated with significant 
morbidity, mortality and costs. However, precipitating factors leading to HF hospitalization and 
their importance with respect to subsequent outcomes are not well understood.  
Methods and Results: We prospectively collected the symptoms and signs present on 
admission and investigator-identified factors thought to have contributed to the first adjudicated 
HF hospitalization in the Candesartan in Heart Failure Assessment of Reduction in Mortality and 
morbidity program (CHARM), stratified by ejection fraction (EF). Potential precipitants were 
collected using a specifically designed case report form and then categorized as cardiovascular 
(CV), non-cardiovascular (non-CV) and unknown. We examined the associations between these 
factors and subsequent re-hospitalization and mortality rates.  
Of 1,668 patients who experienced HF hospitalization, 1,152 had reduced EF (HFrEF; EF 
≤40%) and 516 had preserved EF (HFpEF). Overall, 54% had CV, 32% non-CV, and 14% 
unknown factors thought to have precipitated HF, with similar proportions in HFrEF and HFpEF. 
The most common precipitants were arrhythmia (15%), other non-CV reasons (11%), and 
respiratory infection (10%). Subsequent CV re-admission rates were highest in those whose 
initial HF hospitalization was precipitated by CV factors. However, mortality rates were similar 
among patients with any of the three categories of precipitating factors. Results were similar in 
HFrEF and HFpEF.  
Conclusions: Among chronic HF patients hospitalized for decompensation, the investigator-
reported precipitating factor was not associated with the subsequent mortality rate but was 
associated with the type of re-admission: re-admissions for CV reasons were more likely when 
the index precipitant was CV.  
 
Keywords: Heart failure, hospitalization, precipitating factors, ejection fraction, prognosis  
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Introduction 
Heart failure (HF) is a leading reason for hospitalization in Western populations over the age of 
65 and is associated with significant cost, morbidity, and subsequent mortality.1 Precipitating 
factors leading to HF hospitalization have been identified in prior, mainly retrospective, studies 
and include arrhythmias, myocardial ischemia, infections, worsening renal function, uncontrolled 
hypertension and non-compliance with medications or diet.2-5 However, the relationship 
between these factors and long-term morbidity and mortality, including recurrent 
hospitalizations, is not well understood. Similarly, the clinical signs and symptoms on admission 
in patients hospitalized for HF according to these precipitants are poorly described.  
A better understanding of the effect of precipitating factors of HF hospitalizations is important for 
several reasons. First, the identification of modifiable factors leading to HF hospitalizations may 
help inform strategies to mitigate recurrent admission. Second, the association of these factors 
with recurrent hospitalizations may inform the design of future clinical trials, for instance in the 
selection of high-risk patient populations. Traditionally, only the first hospitalization for HF has 
been analyzed as an endpoint in clinical trial reports and observational studies. However, this 
approach does not consider the burden of recurrent events to patients, the healthcare system 
and payers. Analyses of recurrent hospitalizations among patients with HF are, thus, gaining 
increasing interest and have the potential to improve the efficiency and reduce cost of future 
clinical trials.6, 7 
In this study we examined prospectively collected, investigator-identified, reasons thought to 
have contributed to the first hospitalization for HF in the Candesartan in Heart Failure 
Assessment of Reduction in Mortality and morbidity program (CHARM) and the association 
between these contributors to HF hospitalization and subsequent recurrent admissions, as well 
as the rate and cause of subsequent death. Since literature on the precipitants of HF 
hospitalization in individuals with HFrEF and HFpEFis sparse, we also examined these 
variables stratified by ejection fraction. 
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Methods 
Patient population 
The Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity 
(CHARM) program randomized 7,599 patients with New York Heart Association (NYHA) class 
II-IV HF to candesartan or placebo in addition to standard HF therapy. The design and main 
results of this trial have been previously reported.8 Briefly, the program consisted of three 
concurrent trials (March 1999 – March 2003): CHARM-Alternative included HF patients with an 
EF≤40% who were intolerant to ACE-inhibitors, CHARM-Added included HF patients with an 
EF≤40% who were being treated with an ACE-inhibitor, and CHARM-Preserved included HF 
patients with an EF>40% most of whom were not treated with an ACE-inhibitor. The CHARM 
trials were approved by institutional review boards for each study site and all enrolled patients 
provided informed consent for study participation. Patients were excluded from this analysis if 
there was no primary precipitating factor reported for the first adjudicated HF hospitalization 
(n=7) or if the ejection fraction was not documented (n=1). For the purpose of this analysis, we 
focused on patients with a first adjudicated HF hospitalization (n=1,668). 
 
Outcomes 
The primary outcome of the overall program was all-cause mortality and for the component trials 
it was the composite of cardiovascular (CV) death or hospital admission for HF. First 
hospitalizations for HF were adjudicated, while subsequent HF hospitalizations were 
investigator reported, as were non-HF hospitalizations. The median follow up for the overall 
program was 37.7 months. Due to uncertain discharge dates, 2 patients were excluded from the 
annual incidence rates for HF, CV, non-CV and all-cause readmissions. For patients with 
missing discharge dates for the first HF hospitalization (n=141), discharge dates were imputed 
assuming a 5 day length of stay based on the median hospital length of stay in this trial. 
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Patients who ended study while hospitalized (n=7) did not contribute to the calculation of annual 
incidence rates for HF, CV, non-CV and all-cause readmissions.  
 
Identification of precipitating factors 
When reporting HF hospitalizations after randomization, investigators were asked to report 
possible precipitating and aggravating factors and to assign a primary reason for the HF 
hospitalization to one of several predefined reasons: non-compliance with cardiac medications, 
inappropriate decrease of anti-failure therapy, excessive salt intake/dietary non-compliance, 
cardiac arrhythmias, acute myocardial ischemia/myocardial infarction, anemia, febrile illness, 
other high-output state, excessive alcohol intake, concomitant drug use within previous 48 hours 
(calcium channel blockers, beta-blockers, antiarrhythmic drugs other than amiodarone, non-
steroidal anti-inflammatory drugs), any other non-cardiac precipitating or associated illness or 
factor, precipitating valvular disease, any other precipitating or aggravating factor(s). Only the 
primary precipitant identified by investigators was utilized in this analysis. Of those first 
adjudicated HF hospitalization which were assigned to either “any other non-cardiac 
precipitating or associated illness or factor” (n=282) or to “any other precipitating or aggravating 
factor(s)” (n=543) free text descriptions of the primary reason were individually reviewed by a 
physician and used to reclassify the precipitating factors into specific CV, non-CV and unknown 
factors. 
 
Statistical analyses 
Baseline characteristics for patients according to precipitant factor were compared using chi-
squared or Fisher’s exact test, as appropriate, for categorical and ANOVA for continuous 
variables. In additional analyses, investigator-identified clinical characteristics (HF signs and 
symptoms) and precipitating factors for HF hospitalizations, stratified by those with reduced 
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(≤40%) and preserved (>40%) EF, were analyzed using chi-squared or Fisher’s exact test, as 
appropriate.  
To assess possible associations between precipitating factors leading to the first HF 
hospitalization on subsequent hospitalizations and mortality we compared incident all-cause re-
admission rates by the 3 precipitating factor groups, stratified by EF group, using chi-squared or 
Fisher’s exact test, as appropriate. To assess the cumulative incidence rates of subsequent HF 
hospitalization, the crude number of HF hospitalizations per 100 patient-years of follow up after 
discharge from the initial hospitalization for HF was calculated by dividing the total number HF 
hospitalizations by the total follow up time of all patients in each group. The resulting incidence 
rates, 95% confidence intervals (CI) and p-value were based on the Poisson distribution.9 
All tests were two-sided, and a p-value of <0.05 was considered statistically significant. All 
analyses were conducted using STATA SE, version 12.1 (College Station, TX). 
 
Results 
Baseline characteristics, according to type of precipitant 
Overall, 1,668 patients enrolled in the CHARM program who were hospitalized for HF based on 
adjudication criteria, were included in this analysis. Their baseline characteristics, according to 
type of precipitant, are presented in Table 1. Investigators identified a probable CV precipitant in 
54% (n=895) of first HF hospitalizations, a non-CV precipitant in 32% (n=538) and could not 
identify any precipitant (precipitant unknown) in 14% (n=235). Baseline characteristics were 
broadly similar across the 3 groups. Of all patients hospitalized for HF, 1,152 (69%) had HFrEF 
at baseline and 516 (31%) had HFpEF.   
 
Investigator-identified precipitating factors leading to HF hospitalization 
Among the CV precipitants, the five most commonly reported were: 1) an arrhythmia (HFrEF 
15% vs. HFpEF 16% of all precipitants; 27% vs. 31% of CV precipitants), 2) non-
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compliance/inappropriate decrease in HF therapy (11% vs. 7.6%), 3) dietary 
indiscretion/excessive oral or IV fluids (8.3% vs. 8.5%), 4) myocardial ischemia/angina (7.4 vs. 
8.7%) and 5) worsening HF/disease progression (9.0% vs. 3.3%; p<0.001) (Table 2). Although 
uncommon, uncontrolled hypertension was more often identified as a precipitant in patients with 
HFpEF (in 3.1% of admissions) compared with HFrEF (1.2%; p=0.007).  
Among the non-CV reasons for admission, respiratory infection was by far the most common 
individual precipitant (10% vs. 11% of all precipitants; 32% vs. 33% of non-CV precipitants), with 
worsening renal function (3.1% vs. 4.8%), other infection (1.9% vs. 2.5%) and anemia (1.4% vs. 
3.1%; p=0.018) the other most commonly identified precipitants. Although less common, a 
diabetes-related reason was more commonly reported as a precipitating factor in HFpEF (0.2% 
vs. 1.4%; p=0.005) and physical exertion more frequently in HFrEF (1.1% vs. 0%; p=0.013). 
There was also a large category of “other” non-CV precipitants (11% vs.10%). 
The proportion of patients with an unknown reason for HF hospitalization was similar in the two 
HF groups (14% vs 13%).  
 
Investigator–identified clinical evidence of HF, according to type of precipitant 
Investigator-identified symptoms and signs at the time of the first hospitalization for HF were 
similar among the precipitating factor groups, both in HFrEF and HFpEF, with the exception of 
pulmonary edema which was more commonly reported in patients with HFpEF when the 
precipitating factor was thought to be CV (39.7% CV, 29.4% non-CV, 24.6% unknown 
precipitant; p=0.016) (Figure 1). The proportions of patients receiving intravenous diuretics 
(92% HFrEF, 91% HFpEF, p=0.496) and intravenous vasodilators (16% both groups, p=0.935) 
were similar, but patients with HFrEF were more likely to have received intravenous inotropic 
agents than patients with HFpEF (21% vs. 13%, p<0.001).  
 
Precipitating causes and subsequent mortality 
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CV precipitants of hospital admission did not selectively identify patients more likely to die from 
a CV cause (annual incidence rate: 39 (95% CI: 35, 44) per 100 patient-years for HFrEF, 29 
(95% CI: 24, 35) for HFpEF) and a non-CV precipitant of hospitalization (annual incidence rate: 
39 (95% CI: 34, 45) per 100 patient-years for HFrEF, 32 (95% CI: 26, 40) for HFpEF) didn’t 
make a subsequent non-CV death more likely than a CV death (Table 3). Patients with an 
unknown precipitant were at slightly lower risk of death (both all-cause and CV) and this was 
also true for both types of HF (HFrEF and HFpEF). 
 
Precipitating causes and subsequent re-hospitalization 
The picture regarding re-admission was different than that for mortality. The overall re-
admission rate was similar in patients with HFrEF (annual incidence rate: 179 (95% CI: 172, 
186) per 100 patient-years) and HFpEF (173 (95% CI: 164, 184) per 100 patient-years) and 
highest among those with a CV precipitant of their index hospitalization for both HFrEF (187 
(95% CI: 177, 197) per 100 patient-years) and HFpEF (181 (95% CI: 168, 196) per 100 patient-
years)). Compared to patients with a non-CV precipitant of their index admission, those with a 
CV precipitant were relatively more likely to have a subsequent HF (and any CV) admission and 
relatively less likely to have a subsequent non-CV admission. This pattern was apparent in both 
HFrEF and HFpEF (Table 3).  
 
Discussion 
Our main findings were: 1) CV reasons were thought to be the precipitant for HF admissions in 
more than half of cases and non-CV reasons in one third, with the remainder of admissions 
having no prospectively identified precipitant. 2) Among the CV and non-CV precipitants, there 
was no single very common and only a few common causes. 3) The precipitants that were 
identified were largely similar for HFrEF and HFpEF, although there were a few differences. 4) 
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The type of precipitant (CV or non-CV) was not associated with the subsequent cause of death 
but was associated with re-admission type. 
 
Investigator-identified precipitating factors leading to HF hospitalization 
A number of precipitating factors believed to be associated with HF hospitalizations have 
previously been reported but these have almost exclusively been collected retrospectively. One 
exception was the RESOLVD pilot study, in which, among 768 patients with HFrEF, the most 
common primary causes leading to HF hospitalizations were thought to be non-adherence to 
salt restriction (15%), other non-cardiac causes (15%), and inappropriate reductions in HF 
therapy (9%).2 Within the “other” and “other non-cardiac” precipitating factor categories, 
investigators noted respiratory infections, use of a beta-blocker (the study drug metoprolol) and 
excessive fluid intake as most common causes. While the proportion of non-cardiac causes and 
inappropriate reductions in HF therapy were similar in our study, non-adherence in salt 
restriction was reported less frequently in CHARM. This difference could be due to either patient 
education efforts regarding salt restriction in the CHARM cohort or alternative primary 
precipitants (e.g. arrhythmia) which were more commonly identified in CHARM. Although both 
CHARM and RESOLVD were multi-site international trials, geographic variability in salt intake 
may contribute to this difference. In the OPTIMIZE-HF registry of 48,612 patients hospitalized 
for HF (mean EF 39%) in the USA, 61.3% patients had one or more pre-specified precipitating 
factors identified, with pneumonia/respiratory process (15.3%), myocardial ischemia (14.7%), 
and an arrhythmia (13.5%) being most frequent.4 The OPTIMIZE-HF report did not differentiate 
between patients with HFrEF and HFpEF. A more recent international AHF registry (GREAT) of 
15,828 patients hospitalized for HF in Europe and Asia identified one precipitating factor in 49% 
of patients, multiple factors in 6% and no known precipitants in 44%. Of those with a single 
precipitating factor, the most common reported precipitants were acute coronary syndrome 
(52%), atrial fibrillation (16%) and infection (14%).10 The higher rates of precipitant infection and 
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myocardial ischemia in the AHF registries as compared with CHARM may be related to the 
difference between an AHF registry and a chronic HF clinical trial dataset. Since our analysis is 
based on adjudicated HF hospitalizations, myocardial infarctions complicated by AHF would 
have been adjudicated as myocardial infarction rather than HF hospitalization based on the pre-
defined event definitions and respiratory infections without significant concomitant volume 
overload may not have qualified as HF admission.  
Recently, registry data from the US Get With The Guidelines-HF database, a prospective 
observational study of patients hospitalized for HF with documented EF, reported that the most 
common factors thought to precipitate HF hospitalizations included pneumonia/respiratory 
problem (28.2%), arrhythmia (21.7%), medication non-compliance (15.8%), worsening renal 
failure (14.7%), and uncontrolled hypertension (14.5%).5 Some of these factors varied by EF 
group (EF <40%, 40-49%, ≥50%) and were independently associated with hospital length of 
stay and inpatient mortality. Long term outcomes were not reported. This registry also identified 
higher rates of respiratory infection, arrhythmias, medication non-compliance, worsening renal 
function and hypertension than ours. Although the leading precipitating factors were similar to 
ours, the proportions in these groups were higher than in CHARM. Registry cohorts may differ 
from clinical trial cohorts due to exclusion criteria which may select a patient population with 
generally better renal function, blood pressure control and medication compliance, for instance.  
 
Our findings extend those from prior reports. We identified a broad spectrum of CV and non-CV 
reasons thought to have precipitated the index HF hospitalization, with only small differences 
between patients with HFrEF and HFpEF. Several of these factors, both CV and non-CV 
related, are potentially modifiable and could be addressed through close outpatient monitoring, 
patient education and engagement. Based on our data, these strategies should include 
improved management of co-morbidities (atrial fibrillation, hypertension, COPD, diabetes), and 
strategies to improve adherence to evidence based HF therapies. Comprehensive in-hospital 
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and post-discharge programs that focus on these aspects have demonstrated reductions in the 
rate of subsequent readmissions for HF, although no single intervention alone may be sufficient 
to address this complex issue.11 In addition, the number of respiratory infections leading to HF 
exacerbations, which was one of the leading non-CV reasons in our study, could potentially be 
reduced through vaccination programs for influenza and pneumococcal infections.12, 13 Given 
the chronicity and trajectory of HF, some hospitalizations for HF will be unavoidable. However, 
novel strategies for outpatient management through home visits or clinics for IV diuretics have 
the potential to further reduce hospitalizations for HF even in the setting of worsening HF.14  
 
Investigator–identified clinical evidence of HF 
There were no important differences with respect to symptoms and clinical signs between the 
precipitant factor groups with the exception that pulmonary edema was more commonly 
reported in HFpEF patients with a CV precipitant. This may be an indicator of a higher degree of 
volume overload in this subgroup of patients.  
 
Recurrent hospitalizations and mortality 
Prior data on the long term outcomes based on precipitants leading to an initial hospitalization 
for HF are sparse. We found that patients with a CV precipitant of their index HF hospitalization 
had the highest annual incidence rate of CV readmissions adding information to the previous 
report about subsequent risk following a hospitalization for HF.15 This insight may be relevant 
both clinically and for research purposes. If a specific CV cause, such as uncontrolled 
hypertension, can be addressed, subsequent hospitalization could potentially be prevented.  
Few other studies have investigated the relationship between potential HF hospitalization 
precipitating factors and risk of re-admission and mortality. In the OPTIMIZE-HF registry 
(n=5,791, mean EF 37%), myocardial ischemia and worsening renal function were associated 
with a higher risk of 60- to 90-day all-cause mortality whereas uncontrolled hypertension as a 
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precipitating factor was associated with lower rates of post-discharge death or readmission. In 
the GREAT registry (n=15,828, mean EF 38%) 90-day all-cause mortality was highest in 
patients in whom AHF was thought to have been precipitated by acute coronary syndrome or 
infection (HR 1.69, 95% CI 1.44-1.97 and HR 1.51, 95% CI 1.18-1.92).10 Analyses were not 
stratified by EF. In CHARM, rates of CV and all-cause mortality were similar among the three 
precipitating factor categories in patients with HFrEF and HFpEF but were overall higher in 
those with HFrEF, in concordance with prior analyses stratified by EF.7  
Our findings suggest that precipitating factors leading to the initial HF hospitalization may be 
associated with the rate of recurrent admissions rather than subsequent mortality. This finding 
could be due to a number of reasons but it may be that CV precipitants are more persistent or 
likely to recur (e.g. atrial fibrillation, myocardial ischemia) than non-CV causes, e.g. respiratory 
infection. It is also possible that based on the precipitant, certain conditions may be more or less 
likely to be amendable to outpatient management in patients with known HF so that patients re-
presenting with CV problems, e.g. arrhythmias, are more likely to be admitted, whereas non-CV 
problems, e.g. certain infections, may be managed in the outpatient setting.  
 
Limitations 
These data should be interpreted in the context of their limitations. First, only the initial HF 
hospitalization was adjudicated by an independent committee, all subsequent hospitalizations 
were investigator reported. It is possible that some of these events would not meet the criteria 
used by an endpoint committee. In addition, subsequent hospitalizations may have been 
influenced by the type of precipitant (CV vs. non-CV) whereas mortality was adjudicated in all 
cases. However, the same data collection forms were used for all events and should have led to 
consistent data collection for subsequent events. Removal of additional events would have led 
to an underestimation of the number of recurrent hospitalizations in this cohort. Second, this 
analysis focused on the primary factor leading to the first adjudicated hospitalization for HF, 
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additional secondary factors were not analyzed in this manuscript and precipitating factors 
leading to subsequent HF hospitalizations were also not analyzed with respect to CV, non-CV 
and unknown factors. It is possible that both during the initial and subsequent hospitalizations 
multiple factors contributed to patients’ worsening HF.  In addition, patient-identified precipitating 
factors for HF hospitalizations may differ from investigator-identified reasons for admission but 
these were not collected in this trial.16, 17 Third, EFs were reported by the study sites and not 
verified by an independent core imaging laboratory. Fourth, the cut off values for HFrEF 
(EF≤40%) and HFpEF (EF>40%) in this analysis were based on the study design of CHARM. 
Due to the small size of the group with an EF ≥40% we were unable to further divide this group 
into the recently proposed HFmrEF (EF 40-50%) and HFpEF (>50%) classifications.18 Future 
investigations in larger cohorts should describe precipitating factors based on the new 
classifications. Finally, although our analyses were stratified by EF, we did not adjust for 
potential additional confounders in this hypothesis-generating report.  
 
Conclusions 
Among chronic HF patients hospitalized for decompensation, the investigator-reported 
precipitating factor was not associated with the subsequent mortality rate (or cause of death) but 
was associated with the type of re-admission: re-admissions for CV reasons were more likely 
when the index precipitant was CV. These findings may have implications for developing 
strategies to prevent readmissions and inform the design of future trials. 
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Table 1. Baseline characteristics (n=1,668)  
 
 CV reasons 
(n=895) 
Non-CV 
reasons 
(n=538) 
Unknown 
reason 
(n=235) 
P 
Demographics     
Age (years) 68 (11) 68 (11) 67 (11) 0.199 
Men 614 (69) 360 (67) 168 (72) 0.449 
Ethnicity    <0.001 
European 786 (88) 488 (91) 193 (82) 0.003 
Black 55 (6.2) 22 (4.1) 9 (3.8) 0.163 
Other  54 (6.0) 28 (5.2) 33 (14) <0.001 
Clinical characteristics     
NYHA class    0.559 
II 290 (32) 160 (30) 81 (35)  
III 557 (62) 348 (65) 138 (59)  
IV 48 (5.4) 30 (5.6) 16 (6.8)  
Mean LVEF (%) 35 (15) 37 (15) 35 (14) 0.281 
Heart rate (bpm) 75 (14) 74 (12) 76 (14) 0.403 
Systolic BP (mmHg) 129 (20) 130 (20) 127 (20) 0.269 
Diastolic BP (mmHg) 75 (11) 74 (11) 75 (11) 0.277 
BMI (kg/m2) 28 (6) 29 (6) 27 (6) 0.021 
Clinical evidence of HF     
Dyspnea when walking on 
level ground 
634 (71) 401 (75) 178 (76) 0.167 
Orthopnea 246 (28) 158 (29) 62 (26) 0.631 
PND 168 (19) 101 (19) 41 (18) 0.889 
JVD 126 (14) 69 (13) 34 (15) 0.751 
Crackles (any) 202 (23) 127 (24) 59 (25) 0.696 
S3 143 (16) 100 (19) 34 (15) 0.279 
Peripheral edema 306 (34) 202 (38) 77 (33) 0.316 
Medical history     
Hospital admission for HF 749 (84) 449 (84) 204 (87) 0.463 
Myocardial infarction 481 (54) 286 (53) 129 (55) 0.906 
Stroke 98 (11) 59 (11) 23 (10) 0.866 
Diabetes mellitus 352 (39) 239 (44) 94 (40) 0.155 
Hypertension 530 (59) 318 (59) 124 (53) 0.181 
Atrial fibrillation 309 (35) 191 (36) 81 (35) 0.924 
Pacemaker/ICD 133 (15) 82 (15) 44 (19) 0.338 
ECG: Bundle branch block 279 (31) 175 (33) 74 (32) 0.698 
Current smoker 108 (12) 72 (13) 40 (17) 0.134 
Cancer 72 (8.0) 46 (8.6) 10 (4.3) 0.099 
HF etiology     
Ischemic  538 (60) 329 (61) 151 (64) 0.510 
Idiopathic dilated 
cardiomyopathy 
157 (18) 87 (16) 43 (18) 0.715 
Hypertensive 113 (13) 70 (13) 23 (9.8) 0.426 
Valvular  33 (3.7) 18 (3.4) 5 (2.1) 0.549 
Diabetes 3 (0.3) 0 4 (1.7) 0.007 
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Alcohol related 8 (0.9) 3 (0.6) 0 0.369 
Atrial fibrillation 24 (2.7) 12 (2.2) 4 (1.7) 0.715 
Other 19 (2.1) 19 (3.5) 5 (2.1) 0.268 
Medical treatment     
ACE inhibitor 414 (46) 258 (48) 112 (48) 0.804 
Betablocker 409 (46) 236 (44) 108 (46) 0.768 
Diuretic 839 (94) 504 (94) 226 (96) 0.337 
Spironolactone 186 (21) 120 (22) 54 (23) 0.679 
Digoxin 491 (55) 287 (54) 117 (50) 0.376 
Calcium channel blocker 169 (19) 120 (22) 34 (15) 0.035 
Long acting nitrates 381 (43) 204 (38) 88 (38) 0.137 
Oral anticoagulants 353 (39) 204 (38) 84 (36) 0.559 
Aspirin 439 (49) 279 (52) 120 (51) 0.567 
 
Legend: 
Categorical variables are presented as counts (percentages), continuous variables as means 
(SD), unless otherwise specified. 
NYHA: New York Heart Association class, LVEF: Left ventricular ejection fraction, BP: Blood 
pressure, BMI: Body mass index, HF: Heart failure, PND: Postural nocturnal dyspnea, JVD: 
Jugular venous distension, ICD: Implanted cardiac defibrillator, ECG: Electrocardiogram, ACE: 
Angiotensin converting enzyme. 
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Table 2. Physician-identified primary reason for worsening heart failure leading to first 
heart failure hospitalization 
 
n (%) All patients 
(n=1,668) 
EF≤40% 
(n=1,152) 
EF>40% 
(n=516) 
P* 
Cardiovascular reasons  895 (54) 628 (55) 267 (52) 0.294 
Arrhythmia 252 (15) 169 (15) 83 (16) 0.456 
Non-compliance/inappropriate 
decrease in HF therapy 
160 (9.6) 121 (11) 39 (7.6) 0.059 
Dietary indiscretion/excessive 
oral fluid intake/IV fluids 
139 (8.3) 95 (8.3) 44 (8.5) 0.848 
Myocardial ischemia/angina 130 (7.8) 85 (7.4) 45 (8.7) 0.344 
Worsening HF/disease 
progression 
121 (7.3) 104 (9.0) 17 (3.3) <0.001 
Valvular disease 42 (2.5) 25 (2) 17 (3.3) 0.175 
Uncontrolled hypertension 30 (1.8) 14 (1.2) 16 (3.1) 0.007 
Other CV reasons  21 (1.3) 15 (1.3) 6 (1.2) 0.814 
Non-cardiovascular reasons  538 (32) 358 (31) 180 (35) 0.124 
Respiratory infection 174 (10) 115 (10) 59 (11) 0.370 
Worsening renal function/renal 
failure 
61 (3.7) 36 (3.1) 25 (4.8) 0.084 
Other infection 35 (2.1) 22 (1.9) 13 (2.5) 0.422 
Anemia 32 (1.9) 16 (1.4) 16 (3.1) 0.018 
COPD/asthma 16 (1.0) 13 (1.1) 3 (0.6) 0.417 
Exertion/increased exercise 13 (0.8) 13 (1.1) 0 0.013 
Depression/anxiety/emotional 
stress 
10 (0.6) 7 (0.6) 3 (0.6) 0.949 
Diabetes/diabetes medication 
related reasons 
9 (0.5) 2 (0.2) 7 (1.4) 0.005 
NSAID use 9 (0.5) 7 (0.6) 2 (0.4) 0.729 
Other non-CV reasons 179 (11) 127 (11) 52 (10) 0.564 
Unknown reason 235 (14) 166 (14) 69 (13) 0.573 
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Legend: 
*Chi squared or Fisher’s exact test comparing two EF groups, as appropriate.  
EF: Ejection fraction, HF: Heart failure, CV: Cardiovascular, COPD: Chronic obstructive 
pulmonary disease, NSAID: Non-steroidal anti-inflammatory drugs
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Table 3. Events following first heart failure hospitalization  
 
 
Legend: 
* P value: Global chi squared or Fisher’s exact test, as appropriate, comparing groups A, B and C stratified by EF group. 
** P value: Log rank test comparing groups A, B and C stratified by EF group. 
HF: Heart failure, CV: Cardiovascular, pt: Patient, yrs: Years, CI: Confidence interval  
 First hospitalization for HF 
EF≤40% 
First hospitalization for HF 
EF>40% 
 All HFrEF 
patients 
(n=1,152) 
Group A: 
CV 
reasons 
for HF 
(n=628) 
Group B: 
Non-CV 
reasons 
for HF 
(n=358) 
Group C: 
Unknown 
reasons 
(n=166) 
P All HFpEF 
patients 
(n=516) 
Group A: 
CV 
reasons 
for HF 
(n=267) 
Group B: 
Non-CV 
reasons 
for HF 
(n=180) 
Group C: 
Unknown 
reasons 
(n=69) 
P 
Readmissions following 
1st HF hospitalization 
          
Annual incidence rate of 
all-cause readmissions 
(per 100 pt-yrs; 95% CI)* 
179 
(172, 186) 
187 
(177, 197) 
174 
(162, 187) 
162 
(146, 180) 
0.032 173 
(164, 184) 
181 
(168, 196) 
165 
(149, 182) 
166 
(143, 193) 
0.273 
Annual incidence rate of 
HF readmissions  
(per 100 pt-yrs; 95% CI)* 
79 
(75, 84) 
86 
(80, 93) 
70 
(62, 78) 
74 
(64, 87) 
0.005 59 
(54, 65) 
61 
(53, 69) 
52 
(44, 62) 
71 
(57, 90) 
0.103 
Annual incidence rate of 
CV readmissions  
(per 100 pt-yrs; 95% CI)* 
127 
(121, 133) 
138 
(130, 147) 
111 
(102, 121) 
120 
(107, 136) 
<0.001 108 
(101, 116) 
118 
(108, 130) 
94 
(82, 107) 
106 
(88, 128) 
0.020 
Annual incidence rate of 
non-CV readmissions  
(per 100 pt-yrs; 95% CI)* 
52  
(48, 56) 
49 
(44, 54) 
63 
(56, 71) 
42 
(34, 51) 
<0.001 65  
(59, 71) 
63 
(55, 72) 
71 
(61, 82) 
60 
(47, 78) 
0.433 
 
Mortality following 1st 
HF hospitalization 
          
Annual incidence of all- 
cause death (per 100 pt-
yrs; 95% CI)**  
39 
(36, 42) 
39 
(35, 44) 
39 
(34, 45) 
36 
(29, 45) 
0.913 28 
(25, 33) 
29 
(24, 35) 
32 
(26, 40) 
19 
(13, 30) 
0.136 
Annual incidence of CV 
death (per 100 pt-yrs; 
95% CI)** 
35 
(32, 38) 
35 
(31, 40) 
34 
(29, 40) 
33 
(27, 42) 
0.963 22 
(19, 26) 
22 
(17, 27) 
25 
(20, 33) 
17 
(11, 28) 
0.360 
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Figure 1. Investigator-identified clinical evidence of worsening heart failure at time of first 
HF hospitalization 
 
Panel A: Patients with HFrEF (EF≤40%) (n=1,152) 
Panel B: Patients with HFpEF (EF>40%) (n=516) 
 
Legend: 
* P<0.05 for comparison between precipitating factor groups 
HFrEF: Heart failure with reduced ejection fraction, HFpEF: Heart failure with preserved ejection 
fraction, CV: Cardiovascular, JVP: Jugular venous pressure, CXR: Chest x-ray  
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Figure 2. Annual incidence rates of events following first heart failure hospitalization 
 
Panel A: HFrEF (EF≤40%) (n=1,152)    
Panel B: HFpEF (EF>40%) (n=516) 
 
Legend: 
HFrEF: Heart failure with reduced ejection fraction, HFpEF: Heart failure with preserved ejection 
fraction, CV: Cardiovascular 
 
 
